Clinical Trial Update: Study of Subcutaneous Campath-1H in Patients With B-Cell CLL and Residual Disease After Chemotherapy [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating subcutaneous Campath-1H (alemtuzumab) in patients with B-cell chronic lymphocytic leukemia who have residual disease after chemothera…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Chronic Lymphocytic Leukemia

Drugs mentioned

• Campath-1H (alemtuzumab)

Snippet

Sponsor: Chronic Lymphocytic Leukemia Research Consortium | Conditions: B-Cell Chronic Lymphocytic Leukemia | Phase 2 | Status: UNKNOWN